+44 (0)1509 263171
Please use this identifier to cite or link to this item:
|Title: ||Imaging of myocardial fibrosis in patients with end-stage renal disease: Current limitations and future possibilities|
|Authors: ||Graham-Brown, Matthew P.M.|
Stensel, David J.
March, Daniel S.
McCann, Gerry P.
Burton, James O.
|Keywords: ||Cardiac MRI|
End stage renal disease
|Issue Date: ||2017|
|Publisher: ||© M. P. M. Graham-Brown et al. Published by Hindawi.|
|Citation: ||GRAHAM-BROWN, M.P.M. ... et al, 2017. Imaging of myocardial fibrosis in patients with end-stage renal disease: Current limitations and future possibilities. BioMed Research International, Volume 2017, Article ID 5453606.|
|Abstract: ||Cardiovascular disease in patients with end-stage renal disease (ESRD) is driven by a different set of processes than in the general population. These processes lead to pathological changes in cardiac structure and function that include the development of left ventricular hypertrophy and left ventricular dilatation and the development of myocardial fibrosis. Reduction in left ventricular hypertrophy has been the established goal of many interventional trials in patients with chronic kidney disease, but a recent systematic review has questioned whether reduction of left ventricular hypertrophy improves cardiovascular mortality as previously thought. The development of novel imaging biomarkers that link to cardiovascular outcomes and that are specific to the disease processes in ESRD is therefore required. Postmortem studies of patients with ESRD on hemodialysis have shown that the extent of myocardial fibrosis is strongly linked to cardiovascular death and accurate imaging of myocardial fibrosis would be an attractive target as an imaging biomarker. In this article we will discuss the current imaging methods available to measure myocardial fibrosis in patients with ESRD, the reliability of the techniques, specific challenges and important limitations in patients with ESRD, and how to further develop the techniques we have so they are sufficiently robust for use in future clinical trials.|
|Description: ||This is an Open Access Article. It is published by Hindawi under the Creative Commons Attribution 4.0 International Licence (CC BY). Full details of this licence are available at: http://creativecommons.org/licenses/by/4.0/|
|Publisher Link: ||https://doi.org/10.1155/2017/5453606|
|Appears in Collections:||Published Articles (Sport, Exercise and Health Sciences)|
Files associated with this item:
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.